Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282023106> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W4282023106 endingPage "3077" @default.
- W4282023106 startingPage "3077" @default.
- W4282023106 abstract "3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to false negatives. RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants. In this study, we quantify this benefit using a large, real-world clinical dataset to assess actionable fusions detected from RNA in conjunction with DNA profiling. Methods: Using the Tempus Research Database, we retrospectively analyzed a de-identified dataset of ̃80K samples (77.4K patients) profiled with the Tempus xT assay (both DNA-seq with fusion detection in 21 genes and whole exome capture RNA-seq). Only patients that had successful RNA- and DNA-seq were included. Fusions were detected using the Tempus bioinformatic and clinical workflow. Candidate fusions were filtered based on read support thresholds, fusion annotation ( i.e., breakpoints, reading frame, conserved domains), and manual review. OncoKB was used to select fusion alterations in levels 1 and 2 and to identify those indication-matched to targeted therapies. Results: We identified 2118 level 1 and 2 fusion events across 1945 patients across 20 different cancer types. Most fusions were observed in non-small cell lung cancer (NSCLC) (25%) and biliary cancer (9%) samples. Of the 2118 fusion events, 29.1% (616) were detected only through RNA-seq while 4.8% (101) of the events were identifiable only through DNA-seq. Notably, 69.4% of fusions in low-grade glioma and 58.2% in sarcomas were detected only by RNA-seq. When evaluating specific gene fusion events, RNA-seq consistently improved the detection of fusions compared to DNA-seq alone (Table) across all cancer types. A total of 1106 fusions were classified as targetable by OncoKB indication-matched therapies with 19% (214) of these identifiable through RNA-seq alone, 5% (54) by DNA-seq alone, and 76% (838) identifiable through RNA- and DNA-seq. Overall, fusions identified through RNA-seq alone led to a 24% increase in the number of patients who were eligible to receive matched therapies (214 / 892). This included imatinib for patients with CML/BLCL (69.8%), crizotinib for NSCLC (40.3%) and entrectinib for NTRK and ROS1 fusions (32.5%). Conclusions: The addition of RNA-seq to DNA-seq significantly increased the detection of fusion events and ability to match patients to targeted therapies. Results support consideration of combined RNA-DNA-seq for standard-of-care fusion calling. [Table: see text]" @default.
- W4282023106 created "2022-06-13" @default.
- W4282023106 creator A5004944088 @default.
- W4282023106 creator A5010925062 @default.
- W4282023106 creator A5012787117 @default.
- W4282023106 creator A5018861007 @default.
- W4282023106 creator A5021041237 @default.
- W4282023106 creator A5022782512 @default.
- W4282023106 creator A5029481779 @default.
- W4282023106 creator A5043599202 @default.
- W4282023106 creator A5051259655 @default.
- W4282023106 creator A5065132635 @default.
- W4282023106 creator A5067324005 @default.
- W4282023106 creator A5079945791 @default.
- W4282023106 creator A5080308005 @default.
- W4282023106 creator A5088846258 @default.
- W4282023106 creator A5091723009 @default.
- W4282023106 date "2022-06-01" @default.
- W4282023106 modified "2023-10-16" @default.
- W4282023106 title "Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone." @default.
- W4282023106 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3077" @default.
- W4282023106 hasPublicationYear "2022" @default.
- W4282023106 type Work @default.
- W4282023106 citedByCount "0" @default.
- W4282023106 crossrefType "journal-article" @default.
- W4282023106 hasAuthorship W4282023106A5004944088 @default.
- W4282023106 hasAuthorship W4282023106A5010925062 @default.
- W4282023106 hasAuthorship W4282023106A5012787117 @default.
- W4282023106 hasAuthorship W4282023106A5018861007 @default.
- W4282023106 hasAuthorship W4282023106A5021041237 @default.
- W4282023106 hasAuthorship W4282023106A5022782512 @default.
- W4282023106 hasAuthorship W4282023106A5029481779 @default.
- W4282023106 hasAuthorship W4282023106A5043599202 @default.
- W4282023106 hasAuthorship W4282023106A5051259655 @default.
- W4282023106 hasAuthorship W4282023106A5065132635 @default.
- W4282023106 hasAuthorship W4282023106A5067324005 @default.
- W4282023106 hasAuthorship W4282023106A5079945791 @default.
- W4282023106 hasAuthorship W4282023106A5080308005 @default.
- W4282023106 hasAuthorship W4282023106A5088846258 @default.
- W4282023106 hasAuthorship W4282023106A5091723009 @default.
- W4282023106 hasConcept C104317684 @default.
- W4282023106 hasConcept C10590036 @default.
- W4282023106 hasConcept C107397762 @default.
- W4282023106 hasConcept C111829193 @default.
- W4282023106 hasConcept C121608353 @default.
- W4282023106 hasConcept C126322002 @default.
- W4282023106 hasConcept C150194340 @default.
- W4282023106 hasConcept C162317418 @default.
- W4282023106 hasConcept C16671776 @default.
- W4282023106 hasConcept C2781187634 @default.
- W4282023106 hasConcept C501734568 @default.
- W4282023106 hasConcept C51679486 @default.
- W4282023106 hasConcept C526805850 @default.
- W4282023106 hasConcept C54355233 @default.
- W4282023106 hasConcept C552990157 @default.
- W4282023106 hasConcept C67705224 @default.
- W4282023106 hasConcept C70721500 @default.
- W4282023106 hasConcept C71924100 @default.
- W4282023106 hasConcept C86803240 @default.
- W4282023106 hasConceptScore W4282023106C104317684 @default.
- W4282023106 hasConceptScore W4282023106C10590036 @default.
- W4282023106 hasConceptScore W4282023106C107397762 @default.
- W4282023106 hasConceptScore W4282023106C111829193 @default.
- W4282023106 hasConceptScore W4282023106C121608353 @default.
- W4282023106 hasConceptScore W4282023106C126322002 @default.
- W4282023106 hasConceptScore W4282023106C150194340 @default.
- W4282023106 hasConceptScore W4282023106C162317418 @default.
- W4282023106 hasConceptScore W4282023106C16671776 @default.
- W4282023106 hasConceptScore W4282023106C2781187634 @default.
- W4282023106 hasConceptScore W4282023106C501734568 @default.
- W4282023106 hasConceptScore W4282023106C51679486 @default.
- W4282023106 hasConceptScore W4282023106C526805850 @default.
- W4282023106 hasConceptScore W4282023106C54355233 @default.
- W4282023106 hasConceptScore W4282023106C552990157 @default.
- W4282023106 hasConceptScore W4282023106C67705224 @default.
- W4282023106 hasConceptScore W4282023106C70721500 @default.
- W4282023106 hasConceptScore W4282023106C71924100 @default.
- W4282023106 hasConceptScore W4282023106C86803240 @default.
- W4282023106 hasIssue "16_suppl" @default.
- W4282023106 hasLocation W42820231061 @default.
- W4282023106 hasOpenAccess W4282023106 @default.
- W4282023106 hasPrimaryLocation W42820231061 @default.
- W4282023106 hasRelatedWork W1576119957 @default.
- W4282023106 hasRelatedWork W2075780501 @default.
- W4282023106 hasRelatedWork W2118194624 @default.
- W4282023106 hasRelatedWork W2131677979 @default.
- W4282023106 hasRelatedWork W2734477485 @default.
- W4282023106 hasRelatedWork W2888471641 @default.
- W4282023106 hasRelatedWork W4282023106 @default.
- W4282023106 hasRelatedWork W4288758273 @default.
- W4282023106 hasRelatedWork W4362594036 @default.
- W4282023106 hasRelatedWork W91837152 @default.
- W4282023106 hasVolume "40" @default.
- W4282023106 isParatext "false" @default.
- W4282023106 isRetracted "false" @default.
- W4282023106 workType "article" @default.